Muscoridol (Diclofenac Epolamine)

Diclofenac epolamine inhibits the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in peripheral tissues, which reduces the production of prostaglandins. Lower prostaglandin levels diminish inflammation, edema, and the sensitisation of pain receptors, providing localized analgesic and anti‑inflammatory effects at the site of application.

The appropriate dose of Muscoridol is determined by the prescribing healthcare professional based on the severity of symptoms, the area to be treated, and individual patient factors. Patients should follow the prescriber's instructions and the product label for the amount and frequency of application.

Safety of topical diclofenac during pregnancy or lactation has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Muscoridol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Muscoridol delivers diclofenac epolamine directly to the skin, offering targeted pain relief with lower systemic exposure compared with oral NSAIDs. This can reduce the risk of gastrointestinal side effects, but local skin reactions may be more common. It is an alternative when systemic NSAID therapy is contraindicated or when localized treatment is preferred.

Muscoridol should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme heat to maintain stability and efficacy.

Muscoridol is applied topically to clean, dry skin over the affected area. A thin layer is spread gently and massaged until absorbed, typically 2–4 times daily as directed by the prescriber. Hands should be washed after application, and the treated area should not be covered with occlusive dressings unless advised.

Serious risks, though rare, include severe allergic reactions such as angio‑edema, Stevens‑Johnson syndrome, toxic epidermal necrolysis, systemic NSAID toxicity leading to gastrointestinal bleeding, hepatic injury, and renal impairment. Patients should seek immediate medical attention if they experience signs of a severe reaction.

Muscoridol should be avoided in individuals with known hypersensitivity to diclofenac, other NSAIDs, or any excipients in the formulation. It is also contraindicated on infected, broken, or ulcerated skin, and in patients with a history of severe cardiovascular, gastrointestinal, hepatic or renal disease unless specifically directed by a physician.